Personalis Shares Jump on Medicare Approval for Lung Cancer Test

Shares of the California-based firm advanced 11% during midday trading on Tuesday as investors reacted to the reimbursement news. The stock has maintained a robust trajectory over the last year, gaining 73% in the past 12 months and hitting a 52-week high of $11.50 on Jan. 22.

Clinical Validation and Market Impact

The company stated that the Medicare coverage is supported by clinical evidence produced through its collaboration with the TRACERx consortium (TRAcking Cancer Evolution through therapy). Data from this study demonstrated the test’s ability to identify residual disease with high accuracy, validating its performance in clinical settings for lung cancer patients.

By securing this coverage, Personalis positions its liquid biopsy technology as a standard tool for monitoring cancer recurrence. The NeXT Personal test aims to detect molecular traces of a tumor before they become visible on traditional scans, potentially allowing for earlier intervention in one of the most common forms of the disease.